News

Meet us at Bio€quity 2022 | UGISense will attend Bio€quity 2022, which will take place in 17 – 18 May 2022 in Milan

May 10, 2022

Oligonucleotide Production for Future Blockbuster Applications Is Challenging

April 28, 2022

UGISense and Boehringer Ingelheim enter into an agreement for specific Ugimers™ in animal parasitic diseases

March 15, 2022

UGISense AG Raises its Series B Round to Advance its Oncology Program Towards Pre-clinical and Clinical Development

April 29, 2021

BIO Europe

September 11, 2020

16th Annual Meeting of the Oligo Nucleotide Therapeutics Society

UGISense AG secures new financing

June 20, 2018

Dortmund, June 19, 2018 – Following the seed financing round in 2016, UGISense AG has again been able to successfully complete a funding round.

LDC and UGISense AG to Collaborate on New Drug Class

October 10, 2016

Dortmund, October 12, 2016 – Lead Discovery Center GmbH (LDC) and the biotech company UGISense AG are about to initiate a collaboration to jointly develop innovative drugs using the proprietary UgimeresTM antisense platform.